Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)
In today’s era of individualized precision medicine drug repurposing represents a promising approach to offer patients fast access to novel treatments. Apart from drug repurposing in cancer treatments, cardiovascular pharmacology is another attractive field for this approach. Patients with angina pe...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-06-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1156456/full |
| _version_ | 1827924238498004992 |
|---|---|
| author | Johanna McChord Valeria Martínez Pereyra Sarah Froebel Raffi Bekeredjian Matthias Schwab Matthias Schwab Peter Ong |
| author_facet | Johanna McChord Valeria Martínez Pereyra Sarah Froebel Raffi Bekeredjian Matthias Schwab Matthias Schwab Peter Ong |
| author_sort | Johanna McChord |
| collection | DOAJ |
| description | In today’s era of individualized precision medicine drug repurposing represents a promising approach to offer patients fast access to novel treatments. Apart from drug repurposing in cancer treatments, cardiovascular pharmacology is another attractive field for this approach. Patients with angina pectoris without obstructive coronary artery disease (ANOCA) report refractory angina despite standard medications in up to 40% of cases. Drug repurposing also appears to be an auspicious option for this indication. From a pathophysiological point of view ANOCA patients frequently suffer from vasomotor disorders such as coronary spasm and/or impaired microvascular vasodilatation. Consequently, we carefully screened the literature and identified two potential therapeutic targets: the blockade of the endothelin-1 (ET-1) receptor and the stimulation of soluble guanylate cyclase (sGC). Genetically increased endothelin expression results in elevated levels of ET-1, justifying ET-1 receptor blockers as drug candidates to treat coronary spasm. sGC stimulators may be beneficial as they stimulate the NO-sGC-cGMP pathway leading to GMP-mediated vasodilatation. |
| first_indexed | 2024-03-13T05:08:57Z |
| format | Article |
| id | doaj.art-714944f05cef47bea921b10f61fe86d0 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-13T05:08:57Z |
| publishDate | 2023-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-714944f05cef47bea921b10f61fe86d02023-06-16T06:11:03ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-06-011010.3389/fcvm.2023.11564561156456Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA)Johanna McChord0Valeria Martínez Pereyra1Sarah Froebel2Raffi Bekeredjian3Matthias Schwab4Matthias Schwab5Peter Ong6Department of Cardiology and Angiology, Robert-Bosch-Krankenhaus, Stuttgart, GermanyDepartment of Cardiology and Angiology, Robert-Bosch-Krankenhaus, Stuttgart, GermanyDepartment of Cardiology and Angiology, Robert-Bosch-Krankenhaus, Stuttgart, GermanyDepartment of Cardiology and Angiology, Robert-Bosch-Krankenhaus, Stuttgart, GermanyDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, GermanyDepartments of Clinical Pharmacology, and Biochemistry and Pharmacy, University Tübingen, Tübingen, GermanyDepartment of Cardiology and Angiology, Robert-Bosch-Krankenhaus, Stuttgart, GermanyIn today’s era of individualized precision medicine drug repurposing represents a promising approach to offer patients fast access to novel treatments. Apart from drug repurposing in cancer treatments, cardiovascular pharmacology is another attractive field for this approach. Patients with angina pectoris without obstructive coronary artery disease (ANOCA) report refractory angina despite standard medications in up to 40% of cases. Drug repurposing also appears to be an auspicious option for this indication. From a pathophysiological point of view ANOCA patients frequently suffer from vasomotor disorders such as coronary spasm and/or impaired microvascular vasodilatation. Consequently, we carefully screened the literature and identified two potential therapeutic targets: the blockade of the endothelin-1 (ET-1) receptor and the stimulation of soluble guanylate cyclase (sGC). Genetically increased endothelin expression results in elevated levels of ET-1, justifying ET-1 receptor blockers as drug candidates to treat coronary spasm. sGC stimulators may be beneficial as they stimulate the NO-sGC-cGMP pathway leading to GMP-mediated vasodilatation.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1156456/fulldrug repurposingsGC stimulatorsET-1 receptor blockersrefractory anginaANOCA |
| spellingShingle | Johanna McChord Valeria Martínez Pereyra Sarah Froebel Raffi Bekeredjian Matthias Schwab Matthias Schwab Peter Ong Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA) Frontiers in Cardiovascular Medicine drug repurposing sGC stimulators ET-1 receptor blockers refractory angina ANOCA |
| title | Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA) |
| title_full | Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA) |
| title_fullStr | Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA) |
| title_full_unstemmed | Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA) |
| title_short | Drug repurposing—a promising approach for patients with angina but non-obstructive coronary artery disease (ANOCA) |
| title_sort | drug repurposing a promising approach for patients with angina but non obstructive coronary artery disease anoca |
| topic | drug repurposing sGC stimulators ET-1 receptor blockers refractory angina ANOCA |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1156456/full |
| work_keys_str_mv | AT johannamcchord drugrepurposingapromisingapproachforpatientswithanginabutnonobstructivecoronaryarterydiseaseanoca AT valeriamartinezpereyra drugrepurposingapromisingapproachforpatientswithanginabutnonobstructivecoronaryarterydiseaseanoca AT sarahfroebel drugrepurposingapromisingapproachforpatientswithanginabutnonobstructivecoronaryarterydiseaseanoca AT raffibekeredjian drugrepurposingapromisingapproachforpatientswithanginabutnonobstructivecoronaryarterydiseaseanoca AT matthiasschwab drugrepurposingapromisingapproachforpatientswithanginabutnonobstructivecoronaryarterydiseaseanoca AT matthiasschwab drugrepurposingapromisingapproachforpatientswithanginabutnonobstructivecoronaryarterydiseaseanoca AT peterong drugrepurposingapromisingapproachforpatientswithanginabutnonobstructivecoronaryarterydiseaseanoca |